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and 6.8% of patients, respectively) incurred MS-speciﬁc costs
of $12,830, $14,348, and $17,028/employee, respectively.
Finally, employees in Quintile 5 (highest cost, 4.4%, n = 34)
incurred MS-speciﬁc costs of $26,048/employee. Only 18% of
Quintile 1 had DMT, all subjects in Quintiles 2–4 used DMTs,
and 8.8% of Quintile 5 used no DMTs. Although not used for
quintile assignments, “other conditions” costs/employee were
higher in higher cost quintiles, and Quintile 5 non-MS drug
costs/employee were 6.1–8.6 times higher than Quintiles 1–4.
Similarly, indirect costs were generally higher in the more
expensive quintiles. Average ages were similar between quin-
tiles. Quintile 5 was only 47.1% female, while other quintiles
were >60% female. Wide variation in MS-speciﬁc and non-
speciﬁc costs exists among employees with MS. However,
patients in the highest cost quintile may have the most severe
disease, suffer from multiple conditions and receive other drug
treatments. Further investigation is needed to understand the
impact of comorbid conditions on severity.
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OBJECTIVE: Vasospasm is a common complication of aneurys-
mal subarachnoid hemorrhage (SAH), but its economic impact
has not been studied. In this study, we estimated the incremental
impact of angiographic and clinical vasospasm on inpatient costs
and length of stay (LOS) in a cohort of patients hospitalized for
SAH. METHODS: The study cohort consisted of 198 consecu-
tive patients who underwent either endovascular or surgical
treatment for SAH at Duke University Medical Center (DUMC)
from February 1999 to October 2004. Patients were divided into
three subgroups: clinical (+angiographic) vasospasm (n = 64),
angiographic vasospasm only (n = 51), and patients without
vasospasm (n = 83). Direct and overhead inpatient costs were
obtained from the DUMC cost accounting system. Costs for
physician services were assigned using 2006 Medicare reimburse-
ment rates for North Carolina based on CPT codes billed for
physician services provided to patients in the study cohort. Gen-
eralized linear regression models were applied to assess the incre-
mental impact of vasospasm on inpatient costs and LOS while
adjusting for potentially confounding variables. A counterfactual
approach was applied to estimate the adjusted mean cost differ-
ence between subgroups deﬁned by the presence or absence of
vasospasm. RESULTS: The adjusted incremental cost attribut-
able to clinical vasospasm was $41,877, a 41% increase relative
to no vasospasm (95% CI: 23–62%, p < 0.0001). Angiographic
vasospasm was associated with a $24,528 incremental cost, a
24% increase (95% CI: 7–44%, p = 0.0043). LOS was estimated
to be 6.3 days or 39% longer with clinical vasospasm (95% CI:
21–61%, p < 0.0001), and 4.5 days or 28% longer with angio-
graphic vasospasm (95% CI: 9–50%, p = 0.0026) relative to no
vasospasm. Higher costs related to vasospasm remained signiﬁ-
cant after adjusting for differences in LOS. CONCLUSION:
Patients with clinical and/or angiographic vasospasm incur
higher inpatient costs than those without due to longer hospital
stays and receipt of higher intensity care.
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OBJECTIVE: To determine the economic impact of acute medi-
cation overuse among members with migraine or headache
enrolled in a large, national managed care organization (MCO).
METHODS: Commercial MCO members with a diagnosis of
migraine or headache and acute medication prescriptions from
2002–2006 comprised the study population. A novel claims-
based algorithm based on literature review and clinical expert
input was created to establish thresholds of potential overuse.
Two cohorts were identiﬁed: members with evidence of acute
medication overuse (MO) and members without evidence of
medication overuse (non-MO). Cohorts were followed over vari-
able time periods and compared on demographics, comorbidi-
ties, health care resource utilization and costs. RESULTS: A total
of 17,202 individuals met the criteria for medication overuse,
45,659 comprised the non-MO cohort. Most MO patients met
the criteria for medication overuse by exceeding the threshold for
opiates (62%) or triptans (38%). The MO cohort had signiﬁ-
cantly greater migraine/headache-related and all-cause resource
utilization compared with the non-MO cohort. On a per subject
per month basis, all-cause medical costs for the MO cohort were
$1236 compared with $185 for the non-MO cohort (<0.0001);
all-cause pharmacy costs were $483 for the MO cohort and $105
for the non-MO cohort (<0.0001). For migraine/headache-
related medical and pharmacy costs, total medical costs per
subject per month were $209 for the MO cohort and $33
(<0.0001) for the non-MO cohort, while pharmacy costs were
$286 for the MO cohort and $46 (<0.0001) for the non-MO
cohort. CONCLUSION: Members of this MCO with migraine
or headache who overused acute medications utilized more
health care resources and incurred greater costs compared with
members without acute medication overuse. These results
suggest the possibility that alternate treatment strategies that
decrease medication overuse may result in less health care
resource utilization and lower costs.
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OBJECTIVE: Little is known about medical expenditures in the
multiple sclerosis population after the introduction of expensive
disease modifying agents in the 1990s. This study examines new
data from 2000–2005 population-based survey of MS to provide
estimates of health services utilization by disease severity and
controlling for other risk factors. METHODS: We used a sub-
sample (n = 919) of patients with relapsing remitting and second-
ary progressive MS from the Sonya Slifka Longitudinal Multiple
Sclerosis Study that follows a nationally representative cohort of
MS patients. We examined utilization of hospital and outpatient
care, emergency room (ER), therapy, mental health services,
alternative medicine, home health and personal care. For most
utilization categories, we used log-linear negative binomial
regression models to estimate mean utilization, accounted for
possible correlation of observations for the same person by using
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robust standard errors, and applied baseline sampling weights to
obtain estimates representative for the entire US population with
MS. For provider visits and amount of personal care (conditional
on using it), we estimated similar GLS Gaussian models with
logarithmic transformation of the number of services as depen-
dent variable. RESULTS: Use of most medical services increased
signiﬁcantly with the worsening of MS. However, patients with
severe MS (EDSS > 7.0) used the same or fewer services than
patients with EDSS 6.5–7 except for home health and personal
care. Having relapses signiﬁcantly increased use of most catego-
ries of health services. Longer time since diagnosis, after adjust-
ing for MS stage, was associated with a lower level of utilization
of ER, hospital outpatient care, therapy, and alternative medi-
cine. Patients who were not married generally used more services
than married patients. CONCLUSION: While MS places a sub-
stantial ﬁnancial burden on individuals as well as private and
public payers, use of speciﬁc categories of health services varies
signiﬁcantly with MS severity, presence of relapses, and availabil-
ity of informal help.
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OBJECTIVE: The population over 60 years old is increasing in
Mexico, and thus, the prevalence of chronic-degenerative dis-
eases such as the Parkinson’s Disease is increasing. The objective
of this study was to compare the cost-utility of the treatment with
pramipexol vs. the treatment with l-dopa/carbidopa and sus-
tained release l-dopa/carbidopa, from an institutional perspective
in Mexico. METHODS: A cost-utility analysis was performed
using a decision tree model that simulates the cost and Quality
Adjusted Life Years (QALYs) for a hypothetical cohort of
patients recently diagnosed with Parkinson’s Disease, consider-
ing development or not of dyskinesias throughout a temporary
horizon of four years. The utilities for each health state were
obtained from reports in international literature. The model also
considers changes in drug’s dosage or the possibility that the
patient received treatment with both drugs, according to the
response and associated adverse events. Only annual costs per
drug were considered for this analysis, as the rest of the costs are
similar for buyers. Costs were estimated using 2006 prices and
are expressed in US dollars (exchange rate of 10.9 pesos per US
dollar). RESULTS: It was estimated that a patient treated with
pramipexol would have 3.07 QALYs on average vs. 1.96 QALYs
for a patient treated with L-DOPA/carbidopa, and 1.98 QALYs
for sustained release L-DOPA/carbidopa. Annual costs associ-
ated with each treatment are $1177.50 for pramipexol, $225.60
for L-DOPA/carbidopa and $449.90 for sustained release
L-DOPA/carbidopa. The incremental cost per QALY gained was
$3441.70 for pramipexol vs. l-dopa/carbidopa and $2649.8 for
pramipexol compared with sustained release l-dopa/carbidopa.
CONCLUSION: In Mexico, the treatment with pramipexol is a
highly cost-effective alternative to manage Parkinson’s disease
considering the WHO cost-effectiveness threshold of 1GDP.
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OBJECTIVE: Compare annual indirect costs between privately
insured USA employees with multiple sclerosis (MS) and
matched employee controls. METHODS: Employees with 1
MS diagnosis (ICD-9-CM: 340.x) after January 1, 2002, ages
18–64 years, were selected from a privately insured claims data-
base containing disability data from 17 USA companies. Employ-
ees with MS were matched by age and gender to employee
controls without MS. All were required to have continuous
health coverage 3 months before MS diagnosis (baseline) and 12
months after (study period). Chi-squared tests were used to
compare baseline comorbidities and differences in indirect
resource use (disability and medically-related absenteeism). Wil-
coxon rank-sum tests were used for univariate comparisons of
mean disability and medically-related absenteeism days and asso-
ciated annual indirect costs during the study period. RESULTS:
Employees with MS (n = 989) averaged 44 years old, and 66%
were female. Compared with employee controls, employees with
MS had signiﬁcantly higher rates of mental health disorders and
other neurological disorders and physical disorders as measured
by the Charlson Comorbidity Index. Employees with MS were
more likely to have short-term or long-term disability compared
to employee controls (21.4% vs 5.2%, respectively; P < 0.0001),
resulting in a higher mean number of disability days per year
(29.8 vs 4.5, respectively, P < 0.0001). Employees with MS also
had a higher rate of medically-related absenteeism and associated
absenteeism days compared to employee controls. On average,
annual costs for disability were signiﬁcantly higher for employees
with MS ($3868) compared with employee controls ($414);
P < 0.0001. Medically-related absenteeism costs were also higher
for employees with MS compared with controls ($1901 vs
$1003, respectively; P < 0.0001). On average, total indirect
costs for employees with MS was $5769 compared with con-
trols, $1417 (P < 0.0001). CONCLUSION: Indirect costs of
employees with MS were >4 times those of employee controls.
Effective treatments may reduce the burden of this disease in the
workplace.
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OBJECTIVE: Migraines afﬂict about 30 million people in the
United States. Determining how migraineurs differ from non-
migraneurs from the viewpoint of health resource utilization may
provide insights that could lead to more effective care strategies.
The objective of this study is to compare resource utilization
between migraineurs and non-migraineurs. METHODS: Care-
mark administrative pharmacy and medical claims data were
analyzed in this study over a one year period. Individuals with at
least one migraine medical claim (ICD-9 of 346.xx) and one
triptan/ergot claim were used to identify participants with
Migraine. Propensity score matching was used to sample partici-
pants without migraine (controls) matched for age, gender, and
number of co-morbidities. Outcomes included number of visits
and expenditures associated with ofﬁce visits (MD), emergency
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